Quest Diagnostics Inc. - DGX STOCK NEWS

Pat Beall shares her 32-year career journey at Quest Diagnostics, starting as a route service representative (RSR) and progressing to a supervisory role. She highlights the company's growth through acquisitions, emphasizing teamwork and client relationships in the Dallas-Fort Worth and northeastern Texas areas. Beall stresses the importance of patient service and personal initiative for career advancement at Quest. She values the opportunity to mentor new employees and encourages finding fulfillment in one's chosen career path. The story showcases Quest's employee development and long-term retention, reflecting positively on the company's work culture and growth opportunities.

Quest Diagnostics (NYSE: DGX) has announced a definitive agreement to acquire select assets of University Hospitals' outreach laboratory services business in Ohio. This strategic move aims to broaden access to Quest's innovative diagnostic services and extensive test menu across the state. The acquisition is expected to enhance operating efficiency and ensure continued access to affordable care.

Key points of the transaction include:

• Streamlined operations and quality maintenance
• Expanded patient access to Quest's convenient testing sites
• Broader health plan coverage
• Expected completion in Q4 2024, subject to regulatory approval

Financial terms were not disclosed, but the deal aligns with Quest's strategy to optimize laboratory services for quality, innovation, and affordability.

Quest Diagnostics' 2023 Corporate Responsibility Report, themed 'Care at Our Core', highlights the company's commitment to creating a healthier world. CEO Jim Davis emphasizes Quest's role in healthcare innovation and expansion of disease-state testing. Key achievements include:

- Acquisition of Haystack Oncology to improve cancer detection
- Expansion of Alzheimer's test portfolio
- Progress in Quest for Health Equity (Q4HE) initiative with 55 active programs
- Introduction of Quest Mobile™ phlebotomy service
- Relaunch of HealthyQuest employee health program

The report underscores Quest's focus on growth, efficiency, and new solutions to meet customer needs while expanding access to diagnostic services and reducing health disparities.

Quest Diagnostics (NYSE: DGX) has priced a public offering of $1.85 billion in senior notes, consisting of $400 million due 2027 at 4.600%, $600 million due 2029 at 4.625%, and $850 million due 2034 at 5.000%. The offering is expected to close on August 19, 2024. The proceeds will primarily fund the acquisition of LifeLabs, Inc. and for general corporate purposes, potentially including the redemption of $600 million in 3.50% senior notes due 2025. The 2027 and 2029 notes are subject to a special mandatory redemption at 101% of the principal amount if the LifeLabs acquisition is not completed. This offering provides Quest Diagnostics with significant financial flexibility for its strategic initiatives and debt management.

Quest Diagnostics (NYSE: DGX) has introduced 13 new blood tests on questhealth.com to identify micronutrient deficiencies. These tests are designed for individuals who may have insufficient nutrient intake due to dietary restrictions, prescription medications, or chronic health conditions. The panels, ranging from $65 to $299, cater to specific needs such as food allergies, medication regimens, and chronic diseases like Celiac disease and thyroid disorders.

The tests involve physician oversight and can be purchased directly on questhealth.com. After a physician review, individuals can schedule a blood draw at one of Quest's 2,000+ patient service centers. Results are provided in an easy-to-read report on a secure patient portal, with the option to discuss results with an independent physician at no extra cost.

Quest Diagnostics (NYSE: DGX), a leading diagnostic information services provider, has announced a quarterly cash dividend of $0.75 per share. The dividend will be payable on October 21, 2024 to shareholders of record as of October 4, 2024. This announcement demonstrates Quest Diagnostics' commitment to returning value to its shareholders and reflects the company's financial stability and confidence in its future prospects.

A Quest Diagnostics study published in the Journal of Lower Genital Tract Disease reveals significant gaps in STI testing for pregnant women. Analyzing over 4 million pregnancies, researchers found that 4% of women tested positive for chlamydia or gonorrhea in the first trimester. Alarmingly, 35% of these women didn't receive a follow-up negative test before delivery, suggesting potential untreated infections. The study highlights inconsistencies in guideline-based care, with 2% of initially negative patients later testing positive during pregnancy. Researchers recommend improving adherence to existing guidelines and updating recommendations for STI testing to enhance maternal and newborn health outcomes.

Quest Diagnostics celebrated National Logistics Day on June 28th, honoring their logistics professionals who ensure specimen delivery to labs nationwide. The PR highlights Jamie Croft's 13-year journey with Quest, from stat driver to Advanced RSR. Jamie's story showcases Quest's commitment to employee growth and development within the healthcare industry.

Initially aspiring to roles like dental hygienist or nurse, Jamie found her calling in Quest's logistics team. She progressed from weekend route driver to stat position, learning various aspects of logistics operations. Jamie's experience underscores Quest's role in providing career opportunities and fostering a supportive work environment in the medical field.

Quest Diagnostics (NYSE:DGX) has been named to the 2024 Disability Equality Index® Best Places to Work for Disability Inclusion for the seventh consecutive year. The company achieved a top score of 100, improving from 90 in the previous two years. This recognition comes from Disability:IN and the American Association of People with Disabilities (AAPD).

Quest's commitment to disability inclusion is demonstrated through its DiverseAbilities Employee Business Network (EBN), which has over 350 members and focuses on supporting organizations that assist people with disabilities. The company's efforts in creating a diverse, equitable, inclusive, and accessible workplace for its nearly 50,000 employees have been highlighted as key factors in achieving this recognition.

The Disability Equality Index, now in its 10th year, is considered the most comprehensive disability inclusion assessment tool in business, measuring various aspects including culture, leadership, employment practices, and community engagement.